Skip to NavigationSkip to content

TRD

European Commission authorises Janssen’s anti-depressant Spravato

The European Commission has approved Janssen’s nasal spray Spravato (esketamine), which is used to treat major depressive disorder (MDD) that has been treatment resistant (TRD).

Bernardo Soares, Medical Director at Janssen UK, said: “We are proud to be introducing this innovative treatment option, which we hope will help to address a significant unmet need.”

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches